GlaxoSmithKline PLC ADR
$ 59.54
0.71%
25 Feb - close price
- Market Cap 119,475,479,000 USD
- Current Price $ 59.54
- High / Low $ 59.94 / 59.49
- Stock P/E 15.88
- Book Value 5.51
- EPS 3.75
- Next Earning Report 2026-04-29
- Dividend Per Share $0.66
- Dividend Yield 3 %
- Next Dividend Date 2026-04-09
- ROA 0.10 %
- ROE 0.43 %
- 52 Week High 61.21
- 52 Week Low 31.14
About
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Analyst Target Price
$57.10
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-05 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-01 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.6969 | 1.4562 | 1.24 | 1.2 | 0.58 | 1.29 | 1.1 | 1.09 | 0.72 | 1.28 | 0.97 | 0.9 |
| Estimated EPS | 0.6378 | 1.17 | 1.11 | 1.04 | 0.49 | 1.16 | 0.99 | 0.91 | 0.76 | 1.14 | 0.87 | 0.82 |
| Surprise | 0.0591 | 0.2862 | 0.13 | 0.16 | 0.09 | 0.13 | 0.11 | 0.18 | -0.04 | 0.14 | 0.1 | 0.08 |
| Surprise Percentage | 9.2662% | 24.4615% | 11.7117% | 15.3846% | 18.3673% | 11.2069% | 11.1111% | 19.7802% | -5.2632% | 12.2807% | 11.4943% | 9.7561% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.2 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Jan 1970 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-09 | 2026-01-08 | None | 2025-07-10 | 2025-04-10 | 2025-01-09 | 2024-10-10 | 2024-07-11 | 2024-04-11 | 2024-01-11 |
| Amount | $0.485604 | $0.417088 | $0.428118 | $0.429088 | $0.400652 | $0.389052 | $0.385671 | $0.376185 | $0.4060608 | $0.3397772 |
Next Dividend Records
| Dividend per share (year): | $0.66 |
| Dividend Yield | 3% |
| Next Dividend Date | 2026-04-09 |
| Ex-Dividend Date | 2026-02-20 |
Recent News: GSK
2026-02-26 11:52:51
GSK announced that China's National Medical Products Administration has accepted its new drug application for linerixibat for priority review. The drug is intended to treat cholestatic pruritus in adults with primary biliary cholangitis (PBC), a rare autoimmune liver disease, based on positive results from the phase III GLISTEN trial. Linerixibat is currently under regulatory review in several other regions and holds Orphan Drug Designation in the US, EU, and Japan, though it is not yet approved anywhere globally.
2026-02-25 16:52:21
GSK announced that non-executive director Dr. Hal Barron acquired 64 American Depositary Shares (ADS) on February 20, 2026, through his 401(k) plan's dividend reinvestment program. This transaction, valued at $59.52 per ADS, marginally increases Barron’s stake in GSK and enhances transparency regarding insider holdings. Analysts currently rate GSK as a "Hold" with a $70.00 price target.
2026-02-25 15:52:21
GSK has announced an agreement to acquire Canada-based 35Pharma Inc. for $950 million in cash. This acquisition will add HS235, a potential best-in-class activin signalling inhibitor for cardiopulmonary diseases, to GSK's pipeline. HS235 has completed Phase I trials and is designed to treat pulmonary hypertension with reduced bleeding risk and potential metabolic benefits, targeting a market expected to reach $18 billion by 2032.
2026-02-25 07:52:21
GSK announced an agreement to acquire 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million. The acquisition includes HS235, an activin signalling inhibitor in clinical development for cardiopulmonary diseases, particularly pulmonary hypertension (PH). HS235 is designed to potentially reduce bleeding risks and offer metabolic benefits, addressing a significant unmet need in PH treatment.
2026-02-25 07:52:21
GSK plc has announced an agreement to acquire 35Pharma for $950 million in cash. The acquisition will bring HS235, an investigational medicine that has completed phase I trials, into GSK's pipeline for pulmonary arterial hypertension and pulmonary hypertension due to heart failure. GSK's shares were trading down 0.23% at the time of the announcement.
2026-02-25 07:40:00
GSK Plc has agreed to acquire 35Pharma Inc. for $950 million in cash. This acquisition aims to strengthen GSK's pipeline of experimental therapies by adding 35Pharma's early-stage drug for pulmonary hypertension. The deal allows the UK pharma giant to expand its focus on innovative treatments for heart conditions.
